 |
Adam Bonislawski is the editor of GenomeWeb's ProteoMonitor. He covers proteomics and life science mass spectrometry. E-mail Adam Bonislawski and follow his GenomeWeb Twitter account at @ProteoMonitor. |
Healthlinx Inks Deal to Sell OvPlex Dx to San Diego-Based Startup Mane Cancer Diagnostics
August 31, 2012
Healthlinx Inks Deal to Sell OvPlex Dx to San Diego-Based Startup Mane Cancer Diagnostics
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UPDATE: Vermillion Repays Quest $5.9M, Ending Companies' Credit Agreement
October 19, 2012 / ProteoMonitor - Is Healthlinx Eyeing Purchase of Correlogic's Assets as Part of Move into US Cancer Dx Market?
October 14, 2011 / ProteoMonitor - FDA Grants Fujirebio 510(k) Approval for ROMA Ovarian Cancer Dx, Potential Rival to Vermillion's OVA1
September 9, 2011 / ProteoMonitor - People in the News: Mane Cancer Diagnostics and More
August 31, 2012 / ProteoMonitor - Court Approves Sale of Correlogic’s Assets to Vermillion after Second Bidder Drops Out
December 2, 2011 / ProteoMonitor